unknown
Stage
2016
Founded
3
Investors
About
Aleta Biotherapeutics develops novel CAR T engager proteins designed to improve the efficacy of CAR T cell therapies in treating cancers such as lymphoma, myeloma, and acute myeloid leukemia.
Explore Aleta Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.